Monitoring the antioxidant mediated chemosensitization and ARE-signaling in triple negative breast cancer therapy

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Foygel, Kira ^a   Sekar, Thillai V ^a   Paulmurugan, Ramasamy ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; CISPLATIN; EPIGALLOCATECHIN GALLATE; FLUOROURACIL; KELCH LIKE ECH ASSOCIATED PROTEIN 1; METHYL METHANE SULPHONATE; PLASMID VECTOR; PTEROSTILBENE; RESVERATROL; RRX 001; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; CATECHIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT RESPONSIVE ELEMENT; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CHEMOSENSITIZATION; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; LUCIFERASE ASSAY; MDA MB231 CELL LINE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; CELL PROLIFERATION; DNA RESPONSIVE ELEMENT; DRUG EFFECTS; DRUG SCREENING; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; NUDE MOUSE; OXIDATIVE STRESS; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; WESTERN BLOTTING;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; BLOTTING, WESTERN; CATECHIN; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MICE; MICE, NUDE; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84951177251     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141913     Document Type: Article

References (29)

1. Kobayashi M, Yamamoto M. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Advances in enzyme regulation. 2006; 46:113-40. Epub 2006/08/ 05. doi: 10.1016/j.advenzreg.2006.01.007 PMID: 16887173.
2. Kobayashi M, Yamamoto M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxidants & redox signaling. 2005; 7(3-4):385-94. Epub 2005/02/12. doi: 10.1089/ ars.2005.7.385 PMID: 15706085.
3. Huang HC, Nguyen T, Pickett CB. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem. 2002; 277(45):42769-74. Epub 2002/ 08/29. doi: 10.1074/jbc.M206911200 M206911200 [pii]. PMID: 12198130
4. Zhang DD. The Nrf2-Keap1-ARE signaling pathway: The regulation and dual function of Nrf2 in cancer. Antioxidants & redox signaling. 2010; 13(11):1623-6. Epub 2010/05/22. doi: 10.1089/ars.2010.3301 PMID: 20486759.
5. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 2008; 29(6):1235-43. Epub 2008/ 04/17. doi: bgn095 [pii] doi: 10.1093/carcin/bgn095 PMID: 18413364; PubMed Central PMCID: PMC3312612.
6. Lewis KN, Mele J, Hayes JD, Buffenstein R. Nrf2, a guardian of healthspan and gatekeeper of species longevity. Integrative and comparative biology. 2010; 50(5):829-43. Epub 2010/10/30. doi: 10.1093/ icb/icq034 PMID: 21031035; PubMed Central PMCID: PMC2965188.
7. Zheng H, Whitman SA, Wu W, Wondrak GT, Wong PK, Fang D, et al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes. 2011; 60(11):3055-66. Epub 2011/ 10/26. doi: 60/11/3055 [pii] doi: 10.2337/db11-0807 PMID: 22025779; PubMed Central PMCID: PMC3198067.
8. Cheng X, Chapple SJ, Patel B, Puszyk W, Sugden D, Yin X, et al. Gestational diabetes mellitus impairs Nrf2-mediated adaptive antioxidant defenses and redox signaling in fetal endothelial cells in utero. Diabetes. 2013; 62(12):4088-97. Epub 2013/08/27. doi: db13-0169 [pii] doi: 10.2337/db13-0169 PMID: 23974919; PubMed Central PMCID: PMC3837032.
9. Marchan R, Bolt HM. The cytoprotective and the dark side of Nrf2. Arch Toxicol. 2013; 87(12):2047-50. Epub 2013/11/16. doi: 10.1007/s00204-013-1165-7 PMID: 24232176.
10. Canning P, Cooper CD, Krojer T, Murray JW, Pike AC, Chaikuad A, et al. Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases. J Biol Chem. 2013; 288(11):7803-14. Epub 2013/01/26. doi: M112.437996 [pii] doi: 10.1074/jbc.M112.437996 PMID: 23349464; PubMed Central PMCID: PMC3597819.
11. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res. 2008; 58(5-6):262-70. Epub 2008/10/08. doi: S1043-6618(08)00162-X [pii] doi: 10.1016/j.phrs.2008.09.003 PMID: 18838122; PubMed Central PMCID: PMC2652397.
12. Canning P, Sorrell FJ, Bullock AN. Structural basis of KEAP1 interactions with Nrf2. Free radical biology & medicine. 2015. doi: 10.1016/j.freeradbiomed.2015.05.034 PMID: 26057936.
13. Theodore M, Kawai Y, Yang J, Kleshchenko Y, Reddy SP, Villalta F, et al. Multiple nuclear localization signals function in the nuclear import of the transcription factor Nrf2. J Biol Chem. 2008; 283(14):8984-94 doi: 10.1074/jbc.M709040200 PMID: 18238777; PubMed Central PMCID: PMC2276363.
14. Gupta SC, Kannappan R, Reuter S, Kim JH, Aggarwal BB. Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci. 2011; 1215:150-60. Epub 2011/01/26. doi: 10.1111/j.1749-6632.2010.05852.x PMID: 21261654; PubMed Central PMCID: PMC3060406.
15. Ramkumar KM, Sekar TV, Foygel K, Elango B, Paulmurugan R. Reporter protein complementation imaging assay to screen and study Nrf2 activators in cells and living animals. Anal Chem. 2013; 85 (15):7542-9. Epub 2013/07/06. doi: 10.1021/ac401569j PMID: 23826874; PubMed Central PMCID: PMC3759980.
16. Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox SJ. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012; 72(10):2600-8. Epub 2012/05/17. doi: 72/10/2600 [pii] doi: 10.1158/0008-5472. CAN-11-2303 PMID: 22589277.
17. Bach MK, Brashler JR, Johnson MA. Inhibition by sulfasalazine of LTC synthetase and of rat liver glutathione S-transferases. Biochem Pharmacol. 1985; 34(15):2695-704. Epub 1985/08/01. doi: 0006-2952 (85)90570-2 [pii]. PMID: 2861822.
18. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 2004; 64(12):4294-301. Epub 2004/06/19. doi: 10.1158/0008-5472.CAN-03-3884 64/12/4294 [pii]. PMID: 15205344.
19. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989; 16(4):215-37 Epub 1989/04/01. doi: 10.2165/00003088-198916040-00002 PMID: 2656050.
20. Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res. 1999; 5(10):2908-17. Epub 1999/10/28. PMID: 10537360.
21. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997; 57(19):4285-300. Epub 1997/10/23 22:22. PMID: 9331090.
22. Chung WJ, Sontheimer H. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. J Neurochem. 2009; 110(1):182-93. Epub 2009/05/22. doi: JNC6129 [pii] doi: 10.1111/j.1471-4159.2009.06129.x PMID: 19457125; PubMed Central PMCID: PMC3031868.
23. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem. 1986; 261 (33):15544-9. Epub 1986/11/25. PMID: 3782078.
24. Chao CC, Huang YT, Ma CM, Chou WY, Lin-Chao S. Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line. Mol Pharmacol. 1992; 41 (1):69-75. Epub 1992/01/01. PMID: 1346333.
25. Duriez PJ, Shah GM. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol. 1997; 75(4):337-49. Epub 1997/01/01. PMID: 9493956.
26. Khan K, Araki K, Wang D, Li G, Li X, Zhang J, et al. Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck. 2010; 32(3):381-91. Epub 2009/ 08/13. doi: 10.1002/hed.21195 PMID: 19672867.
27. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-31. Epub 1997/ 02/07. doi: S0092-8674(00)81871-1 [pii]. PMID: 9039259.
28. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med. 2014; 6(221):221ra15. Epub 2014/01/31. doi: 6/221/221ra15 [pii] doi: 10.1126/scitranslmed.3007653 PMID: 24477002.
29. Li N, Nel AE. Role of the Nrf2-mediated signaling pathway as a negative regulator of inflammation: implications for the impact of particulate pollutants on asthma. Antioxid Redox Signal. 2006; 8(1-2):88-98. Epub 2006/02/21. doi: 10.1089/ars.2006.8.88 PMID: 16487041.